Zikani Therapeutics (formerly Macrolide Pharmaceuticals) is utilizing its innovative chemistry technology platform to develop novel Ribosome Targeting Molecules. The company is focused on developing and commercializing therapeutics for patients with limited treatment options. Its scientists start with a rational approach to designing Ribosome Targeting Molecules (RTMs), that expands the structural diversity of these molecules. Their goal is to develop breakthrough RTMs that are orally delivered, safe and potent for the most difficult diseases.
Gurnet Point Capital co-led the Series A financing of Macrolide Pharmaceuticals in March 2015.